Respit

Respit is a veterinary specialty pharmaceutical company that provides regionally specific allergen immunotherapy for pets, including dogs, cats, and horses. Founded by board-certified veterinary dermatologist Jon Plant, DVM, the company offers a "no-test" alternative to traditional allergy testing by utilizing standardized formulations tailored to the most common allergens in specific geographic regions. Its product line includes both injectable and oromucosal spray formulations designed to treat atopic dermatitis and other allergic conditions. The company's approach simplifies the management of pet allergies for veterinarians by removing the need for complex diagnostic testing before starting treatment. In August 2023, Respit was acquired by Vimian Group and integrated into its Nextmune business segment, expanding its reach in the global animal health market.